Share this article
SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2
a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA
® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).
1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis
b and dactylitis
1-8 In addition, the extent of radiographic progression
d was studied through two years. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021.
38 Jazan, Saudi Arabia (22.3%)
15 and Thailand (8.9%).
34 The higher prevalence in the present study could be due to poor quality of diabetes care service, lower level of education, the measurement tool used to quantify the level of diabetic distress, and other forms of stressors.
Several studies among diabetic patients had found higher prevalence of DRD than the present study. Studies that were done in Bangladesh
13 using the DDS-17 scale showed that almost half of patients with T2DM had DRD. Studies in Ghana
19 reported that 44.7% and 51.9% of patients had high levels of DRD, respectively. This discrepancy between the previously reported DRD magnitude and the current prevalence might result from better family and social support implemented in our societies and patients might have under-rated their level of distress. The difference might also be due to variation in coexisting medical problems besides diabetes among study participants. A number of studies have shown that develop